Nu Skin Unfazed By Allegations Of China Violations, Projects More Growth
This article was originally published in The Tan Sheet
Executive Summary
Following allegations from short seller Citron Research that it operates a “pyramid compensation scheme” in China, Nu Skin gives investors a peek into its business model. The firm recorded sales growth of 40% in its second quarter, driven by a 152% jump in China, and “the best is yet to come,” Nu Skin says.
You may also be interested in...
Sales & Earnings In Brief
Sanofi’s Allegra down from year-ago launch as stocking declines; competitive China landscape weighs on Mead Johnson; GNC revenue up double digits across segments; Claritin shows life in Merck consumer unit; USANA reports return to Western growth; Nu Skin preps ageLOC weight management launch.
Nu Skin Secures Future In Genetics Of Aging With LifeGen Acquisition
Nu Skin Enterprises acquires LifeGen Technologies for $11.7 million to ensure that the direct seller’s anti-aging business continues to benefit from LifeGen’s research into the genetic basis for aging.
FDA Crackdown On Anti-Aging Imports Signals "Major Enforcement Initiative"
Increased scrutiny of anti-aging products with sunscreen ingredients entering the U.S. presages "a major enforcement initiative" against personal care product firms making noncompliant claims, according to a food and drug attorney who worked at FDA on import enforcement